Regression of hepatic fibrosis;Regressão da fibrose hepática

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 38, Issue 6, 2005, Pages 514-520

  Andrade, Zilton A ^a,b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b PRONEX FAPESB   (Brazil)

Author keywords

Capillaria hepatica; Hepatic cirrhosis; Hepatic fibrosis; Schistosomiasis

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CAPILLARY; CLINICAL FEATURE; HUMAN; LIVER; LIVER CIRRHOSIS; LIVER FIBROSIS; REMISSION; REVIEW; SCHISTOSOMIASIS;

CAPILLARIA HEPATICA;

EID: 31644441272     PISSN: 00378682     EISSN: 00378682     Source Type: Journal    
DOI: 10.1590/s0037-86822005000600013     Document Type: Review

References (57)

1. Andrade ZA. Evolution and Involution of Hepatosplenic Schistosomiasis. Memórias do Instituto Oswaldo Cruz 84 (supl I): 58-75, 1989.
2. Andrade ZA. Contribution to the study of septal fibrosis of the liver. International Journal of Experimental Pathology 72: 553-562, 1991.
3. Andrade ZA. Extracellular matrix degradation in parasitic diseases. Brazilian Journal of Medical and Biological Research 27: 2273-2281, 1996.
4. Andrade ZA. The situation of hepatosplenic schistosomiasis in Brazil today. Memórias do Instituto Oswaldo Cruz 93 (supl 1) : 313-316, 1998.
5. Andrade ZA, Cheever AW. Characterization of the murine model of schistosomal hepatic periportal fibrosis ("Pipestem" fibrosis). International Journal of Experimental Pathology 74: 195-202, 1993.
6. Andrade ZA, Grimaud JA. Evolution of schistosomal hepatic lesions in mice after curative chemotherapy. The American Journal of Pathology 124: 59-65, 1986.
7. Andrade ZA, Grimaud JA. Morphology of chronic collagen resorption. (A study on the late stages of schistosomal granuloma involution). American Journal of Pathology. 132: 389-399, 1988.
8. Andrade ZA, Peixoto E, Guerret S, Grimaud JA. Hepatic connective tissue changes in hepatosplenic schistosomiasis. Human Pathology 23: 566-573, 1992.
9. Arthur MJP. Matrix degradation in the liver. Seminars in Liver Diseases 10: 47-55, 1990.
10. Arthur MJP. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C (Editorial). Gastroenterology 122: 1525-1528, 2002.
11. Bedossa P, Paradis V. Liver extracellular matrix in health and disease. Journal of Pathology 200: 504-515, 2003.
12. Bhunchet E, Eishi Y, Wake K. Contribution of immune response to hepatic fibrosis by porcine serum. Hepatology 23: 811-817, 1996.
13. Bina JC. Influência da terapêutica específica na evolução da esquistossomose. Tese de Mestrado. Curso de Pós Graduação em Medicina Interna, Universidade Federal da Bahia, Salvador, BA, 1977.
14. Bina JC, Prata A. Regressão da hepatoesplenomegalia pelo tratamento específico da esquistossomose. Revista da Sociedade Brasileira de Medicina Tropical 16: 213-218, 1983.
15. Boros DL. Granulomatous inflammations. Progress in Allergy 24: 183-267, 1983.
16. Brown KE. An overview of hepatic fibrogenesis. Viral Hepatitis Reviews 6: 5-27, 2000.
17. Cameron CR, Ganguly NC. An experimental study of the pathogenesis and reversibility of schistosomal hepatic fibrosis. Journal of Pathology and Bacteriology 87: 217-237, 1964.
18. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. Journal of Hepatology 40: 860-867, 2004.
19. Dietze RS, Prata A. Rate of reversion of hepatosplenic schistosomiasis after specific chemotherapy. Revista da Sociedade Brasileira de Medicina Tropical, 19: 69-73, 1986.
20. Di Vinicius I, Baptista AP, Barbosa Jr AA, Andrade ZA. Morphological signs of cirrhosis regression. (Experimental observations on carbontetrachloride-induced liver cirrhosis in rats). Pathology, Research and Practice, 2005.
21. Ferreira LA, Andrade ZA. Capillaria hepatica: a cause of septal fibrosis of the liver. Memórias do Instituto Oswaldo Cruz 88:441-447, 1993.
22. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. Journal of Biological Chemistry 275: 2247-2250, 2000.
23. Friedman SL. Liver Fibrosis - From bench to bedside. Journal of Hepatology 38: 38-53, 2003.
24. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Seminars in Liver Diseases 21: 311-335, 2001.
25. Geert A, De Bleser P, Hautekeete ML, Niki T, Wisse E. Fat-storing (Ito) cell biology. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA (eds) The liver: Biology and Pathobiology , 3rd edition, Raven Press, New York, p. 819-838, 1994.
26. Gomez DE, De Lorenzo M, Alonso DF, Andrade ZA. Expression of collagenases (MMP1 and MMP9) and their inhibitors (TIMP1 and TIMP2) in schistosomal portal fibrosis. The American Journal of Tropical Medicine and Hygiene 61: 9-13, 1999.
27. Gonnert R. Schistosomiasis studien. IV. Zur Pathologie de Schistosomiasis der Maus. Zeitschrift fur Tropenmedizin und Parasitologie 6: 279-336, 1955.
28. Gross J. How tadpoles lose their tails: path to discovery of the first matrix metalloproteinase. Matrix Biology 23: 3-13, 2004.
29. Henell F, Bricsson JLE, Glaumann H. An electron microscopic study of the post partum involution of the rat uterus: with a note on apparent crinophagy of collagen. Virchows Archives B, Cell Pathology 42: 271-287, 1983.
30. Homeida MA, Ahmed S, Dafalla A, Sulliman S, Eltom I, Nash T, Bennett JL. Morbidity associated with Schistosoma mansoni infection as determined by ultrasound: a study in Gezira, Sudan. The American Journal of Tropical Medicine and Hygiene 39: 196-201, 1988.
31. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJP. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. Journal of Clinical Investigation 102: 538-549, 1998.
32. Katz N, Brener Z. Evolução clínica de 112 casos de esquistossomose mansoni observados após dez anos de permanência em focos endêmicos de Minas Gerais. Revista do Instituto de Medicina Tropical de São Paulo 8: 139-142, 1966.
33. Lemos QT, Magalhães Santos IF, Andrade ZA. Immunological basis of septal fibrosis of the liver in Capillaria hepatica-infected rats. Brazilian Journal of Medical and Biological Research 36: 1201-1207, 2003.
34. Massarrat S, Fallahazad V, Kamalian N. Clinical, biochemical and imagingverified regression of hepatitis B-induced cirrhosis. Liver International 24: 105-109, 2004.
35. Mohamed-Ali Q, Doehring-Schwerdtfeger E, Abdel-Rahim IM, Schlake J, Kardoff R, Franke D, Kaiser C, Elsheikh M, Abdalla S, Schafer P, Ehrich JHH. Ultrasonographic investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity seven months after treatment with praziquantel. The American Journal of Tropical Medicine and Hygiene 44: 444-451, 1991.
36. Okuno M, Moriwaki H, Smai S. Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells. Hepatology 26: 913-921, 1997.
37. Paronetto F, Popper H. Chronic liver injury induced by immunologic reactions. Cirrhosis following immunization with heterologous sera. The American Journal of Pathology 40: 1087-1101, 1966.
38. Perez-Tamayo R. Collagen resorption in carrageenin granulomas. II. Ultrastructure of collagen resorption. Laboratory Investigation 22: 142-157, 1970.
39. Perez-Tamayo R. Cirrhosis of the liver: a reversible disease? Pathology Annual 14: 183-213, 1979.
40. Perez-Tamayo R. Degradation of collagen: pathology. In: Weiss JB, Jayson MIV (eds) Collagen in Health and Disease. Churchill Livingstone, London, p. 135-159, 1982.
41. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Seminars in Liver Diseases 21: 397-416, 2001.
42. Popper H. Pathologic aspects of cirrhosis. A Review. American Journal of Pathology 87: 227-264, 1977.
43. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122: 1303-1313, 2002.
44. Quinn OS, Higginson J. Reversible and irreversible changes in experimental cirrhosis. American Journal of Pathology 47: 353- 369, 1965.
45. Ricard-Blum S, Ville G, Grimaud JA. Pyridinoline, a mature collagen crosslink, in fibrotic livers from Schistosoma mansoni-infected mice. The American Journal of Tropical Medicine and Hygiene 47: 816-820, 1992.
46. Richter J. The impact of chemotherapy on morbidity due to Schistosomiasis. Acta Tropica 86: 161-183, 2003.
47. Rose NR. Mechanisms of autoimmunity. Seminars on Liver Diseases 22: 387-394, 2002.
48. Rubin E, Hutterer F, Popper H. Experimental hepatic fibrosis without hepatocellular regeneration. American Journal of Pathology 52: 111-119, 1968.
49. Schinoni MI, Andrade ZA, Freitas LAR, Oliveira R, Paraná R. Incomplete septal cirrhosis: an enigmatic disease. Liver International, 24: 452-456, 2004.
50. Sciot R, Staessen D, Van Dame B, Van Steenbergen W, Fevery J, de Groote J, Desmet VJ. Incomplete septal cirrhosis: histopathological aspects. Histopathology 13:593-603, 1988.
51. Souza MM. Estudos sobre a fibrose septal hepática induzida por Capillaria hepática (Patogênese e Evolução) Tese de Doutorado, Universidade Federal da Bahia, Salvador, BA, 2003.
52. Souza MM, Paraná R, Trepo C, Barbosa Jr AA, Oliveira I, Andrade ZA. Effect of Interferon-a on Experimental Septal fibrosis of the liver -Study with a new model. Memórias do Instituto Oswaldo Cruz 96: 343-348, 2001.
53. Souza MM, Silva LM, Barbosa Jr A, Oliveira IR, Paraná R, Andrade ZA. Hepatic capillariasis in rats: a new model for testing anti-fibrosis drugs. Brazilian Journal of Medical and Biological Research 33: 1329-1334, 2000.
54. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Archives of Pathology and Laboratory Medicine 124: 1599-1607, 2000.
55. Warren KS. The influence of treatment on the development and course of murine hepatosplenic schistosomiasis mansoni. Transactions of the Royal Society of Tropical Medicine and Hygiene 56: 510-519, 1962.
56. Warren KS. The pathogenesis of "clay-pipe stem cirrhosis" in mice with chronic schistosomiasis mansoni, with a note on the longevity of the schistosomes. The American Journal of Pathology 49: 477-489, 1966.
57. Warren KS, Klein L. Chronic murine hepatosplenic schistosomiasis mansoni: relative irreversibility after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 63: 333-337, 1969.